loading
Moleculin Biotech Inc stock is traded at $1.05, with a volume of 53,823. It is down -1.79% in the last 24 hours and up +0.10% over the past month. Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$1.06
Open:
$1.1
24h Volume:
53,823
Relative Volume:
0.01
Market Cap:
$13.42M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0686
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+9.56%
1M Performance:
+0.10%
6M Performance:
-60.27%
1Y Performance:
-77.52%
1-Day Range:
Value
$1.02
$1.10
1-Week Range:
Value
$0.9502
$1.11
52-Week Range:
Value
$0.3975
$5.47

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Name
Moleculin Biotech Inc
Name
Phone
713-300-5160
Name
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Employee
17
Name
Twitter
@moleculinbio
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
MBRX's Discussions on Twitter

Compare MBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MBRX
Moleculin Biotech Inc
1.05 13.42M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
494.59 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.41 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.50 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
256.38 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.31 24.70B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-12-25 Downgrade Maxim Group Buy → Hold
Jul-18-22 Resumed Oppenheimer Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

pulisher
Apr 21, 2025

Moleculin Biotech Releases Corporate Presentation Online - TipRanks

Apr 21, 2025
pulisher
Apr 18, 2025

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 17, 2025

Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan

Apr 17, 2025
pulisher
Apr 10, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 07, 2025

Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha

Apr 07, 2025
pulisher
Apr 02, 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo

Apr 02, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan

Apr 01, 2025
pulisher
Mar 29, 2025

Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Mar 18, 2025

Moleculin Biotech Inc Stock (MBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Cap:     |  Volume (24h):